Tumors can have varied mutations across different sites. While tissue biopsy focuses on a specific area, liquid biopsy reflects a broader view, capturing genetic alterations from multiple tumor sites, improving overall assessment of tumor heterogeneity.

A dual biopsy NGS approach provides robust insights to guide treatment choices, including the selection of targeted therapies and immunotherapies, maximizing the potential for better patient outcomes

Enhances the ability to detect resistant mutations before they are manifested.

Allows for non-invasive, real-time tracking of tumor dynamics, enabling better assessment of treatment response and disease progression.